A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia

A. A. Hertler, D. M. Schlossman, M. J. Borowitz, G. Laurent, F. K. Jansen, C. Schmidt, A. E. Frankel

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Four patients with chronic lymphocytic leukemia refractory to alkylating agents were treated with T101-ricin A chain immunotoxin (T101-RTA) as part of a phase I study. Over a 4-week period, each patient received eight intravenous infusions of 3 mg/m2 T101-RTA over 1 h. All infusions were well tolerated. Patients had mild fevers but no other systemic toxicities. In vivo binding of T101-RTA was detected by FACS analysis using anti-mouse Ig-FITC or anti-A chain-FITC antibody conjugates. Saturation of circulating leukemic cell-associated target antigen was achieved in three of the patients. Available CD5 sites per cell dropped precipitously at the completion of infusions in all four patients, returning to within 30% of baseline by 24 h. Pharmacokinetic studies revealed rapid clearance of T101-RTA, with wide interpatient variability in peak serum levels (the highest levels in those patients who saturated their circulating CD5 antigen with immunotoxin). Although no patient developed detectable levels of antimurine antibodies, one patient did have a rising titer of anti-ricin A chain antibody associated with declining peak serum levels of immunotoxin. All patients had a rapid fall in WBC count of <24-h duration after each T101-RTA infusion, most likely secondary to the antibody portion of immunotoxin. No sustained benefit could be demonstrated in any patient, possibly because in the absence of an enhancing agent the leukemic cells of all four patients were resistent to T101-RTA at concentrations up to 2,000 ng/ml in vitro.

Original languageEnglish (US)
Pages (from-to)97-113
Number of pages17
JournalJournal of Biological Response Modifiers
Volume7
Issue number1
StatePublished - 1988

Fingerprint

Ricin
Immunotoxins
B-Cell Chronic Lymphocytic Leukemia
Antibodies
Fluorescein-5-isothiocyanate
CD5 Antigens
Alkylating Agents
Serum
Intravenous Infusions
Fever
Pharmacokinetics

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Hertler, A. A., Schlossman, D. M., Borowitz, M. J., Laurent, G., Jansen, F. K., Schmidt, C., & Frankel, A. E. (1988). A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. Journal of Biological Response Modifiers, 7(1), 97-113.

A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. / Hertler, A. A.; Schlossman, D. M.; Borowitz, M. J.; Laurent, G.; Jansen, F. K.; Schmidt, C.; Frankel, A. E.

In: Journal of Biological Response Modifiers, Vol. 7, No. 1, 1988, p. 97-113.

Research output: Contribution to journalArticle

Hertler, AA, Schlossman, DM, Borowitz, MJ, Laurent, G, Jansen, FK, Schmidt, C & Frankel, AE 1988, 'A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia', Journal of Biological Response Modifiers, vol. 7, no. 1, pp. 97-113.
Hertler AA, Schlossman DM, Borowitz MJ, Laurent G, Jansen FK, Schmidt C et al. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. Journal of Biological Response Modifiers. 1988;7(1):97-113.
Hertler, A. A. ; Schlossman, D. M. ; Borowitz, M. J. ; Laurent, G. ; Jansen, F. K. ; Schmidt, C. ; Frankel, A. E. / A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. In: Journal of Biological Response Modifiers. 1988 ; Vol. 7, No. 1. pp. 97-113.
@article{38d5f291a103463588b2b71fee2448cf,
title = "A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia",
abstract = "Four patients with chronic lymphocytic leukemia refractory to alkylating agents were treated with T101-ricin A chain immunotoxin (T101-RTA) as part of a phase I study. Over a 4-week period, each patient received eight intravenous infusions of 3 mg/m2 T101-RTA over 1 h. All infusions were well tolerated. Patients had mild fevers but no other systemic toxicities. In vivo binding of T101-RTA was detected by FACS analysis using anti-mouse Ig-FITC or anti-A chain-FITC antibody conjugates. Saturation of circulating leukemic cell-associated target antigen was achieved in three of the patients. Available CD5 sites per cell dropped precipitously at the completion of infusions in all four patients, returning to within 30{\%} of baseline by 24 h. Pharmacokinetic studies revealed rapid clearance of T101-RTA, with wide interpatient variability in peak serum levels (the highest levels in those patients who saturated their circulating CD5 antigen with immunotoxin). Although no patient developed detectable levels of antimurine antibodies, one patient did have a rising titer of anti-ricin A chain antibody associated with declining peak serum levels of immunotoxin. All patients had a rapid fall in WBC count of <24-h duration after each T101-RTA infusion, most likely secondary to the antibody portion of immunotoxin. No sustained benefit could be demonstrated in any patient, possibly because in the absence of an enhancing agent the leukemic cells of all four patients were resistent to T101-RTA at concentrations up to 2,000 ng/ml in vitro.",
author = "Hertler, {A. A.} and Schlossman, {D. M.} and Borowitz, {M. J.} and G. Laurent and Jansen, {F. K.} and C. Schmidt and Frankel, {A. E.}",
year = "1988",
language = "English (US)",
volume = "7",
pages = "97--113",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia

AU - Hertler, A. A.

AU - Schlossman, D. M.

AU - Borowitz, M. J.

AU - Laurent, G.

AU - Jansen, F. K.

AU - Schmidt, C.

AU - Frankel, A. E.

PY - 1988

Y1 - 1988

N2 - Four patients with chronic lymphocytic leukemia refractory to alkylating agents were treated with T101-ricin A chain immunotoxin (T101-RTA) as part of a phase I study. Over a 4-week period, each patient received eight intravenous infusions of 3 mg/m2 T101-RTA over 1 h. All infusions were well tolerated. Patients had mild fevers but no other systemic toxicities. In vivo binding of T101-RTA was detected by FACS analysis using anti-mouse Ig-FITC or anti-A chain-FITC antibody conjugates. Saturation of circulating leukemic cell-associated target antigen was achieved in three of the patients. Available CD5 sites per cell dropped precipitously at the completion of infusions in all four patients, returning to within 30% of baseline by 24 h. Pharmacokinetic studies revealed rapid clearance of T101-RTA, with wide interpatient variability in peak serum levels (the highest levels in those patients who saturated their circulating CD5 antigen with immunotoxin). Although no patient developed detectable levels of antimurine antibodies, one patient did have a rising titer of anti-ricin A chain antibody associated with declining peak serum levels of immunotoxin. All patients had a rapid fall in WBC count of <24-h duration after each T101-RTA infusion, most likely secondary to the antibody portion of immunotoxin. No sustained benefit could be demonstrated in any patient, possibly because in the absence of an enhancing agent the leukemic cells of all four patients were resistent to T101-RTA at concentrations up to 2,000 ng/ml in vitro.

AB - Four patients with chronic lymphocytic leukemia refractory to alkylating agents were treated with T101-ricin A chain immunotoxin (T101-RTA) as part of a phase I study. Over a 4-week period, each patient received eight intravenous infusions of 3 mg/m2 T101-RTA over 1 h. All infusions were well tolerated. Patients had mild fevers but no other systemic toxicities. In vivo binding of T101-RTA was detected by FACS analysis using anti-mouse Ig-FITC or anti-A chain-FITC antibody conjugates. Saturation of circulating leukemic cell-associated target antigen was achieved in three of the patients. Available CD5 sites per cell dropped precipitously at the completion of infusions in all four patients, returning to within 30% of baseline by 24 h. Pharmacokinetic studies revealed rapid clearance of T101-RTA, with wide interpatient variability in peak serum levels (the highest levels in those patients who saturated their circulating CD5 antigen with immunotoxin). Although no patient developed detectable levels of antimurine antibodies, one patient did have a rising titer of anti-ricin A chain antibody associated with declining peak serum levels of immunotoxin. All patients had a rapid fall in WBC count of <24-h duration after each T101-RTA infusion, most likely secondary to the antibody portion of immunotoxin. No sustained benefit could be demonstrated in any patient, possibly because in the absence of an enhancing agent the leukemic cells of all four patients were resistent to T101-RTA at concentrations up to 2,000 ng/ml in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0023848068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023848068&partnerID=8YFLogxK

M3 - Article

C2 - 3373237

AN - SCOPUS:0023848068

VL - 7

SP - 97

EP - 113

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -